A 60-year-old client newly prescribed atorvastatin 40 mg orally once daily for hyperlipidemia is being given discharge teaching. Which statement by the client indicates the teaching has been effective?
1"I will report any new muscle pain, weakness, tenderness, or dark urine to the provider promptly, and I understand the lab will check my liver enzymes periodically."✓ Correct answer
2"I understand that grapefruit juice is a healthy beverage, so I'll continue drinking it each morning with my atorvastatin since it fits my diet and I enjoy it."
3"Since I've heard that moderate alcohol can improve HDL levels, I'll start having a daily glass of red wine to complement my atorvastatin treatment and protect my heart."
4"When my follow-up labs show that my LDL cholesterol has returned to normal, I'll discontinue the atorvastatin on my own since the medication will have done its job."
Explanation
Statin teaching priorities HMG-CoA reductase inhibitors (-statins) lower LDL by inhibiting hepatic cholesterol synthesis and have proven CV mortality reduction. Three patient-safety priorities: muscle symptom monitoring (myalgia is the most common adverse effect; new pain·weakness·tenderness·dark urine could indicate rhabdomyolysis — report immediately), hepatotoxicity monitoring (baseline LFT and as clinically indicated; report jaundice·RUQ pain·anorexia·dark urine), and drug/food interaction awareness — atorvastatin·simvastatin·lovastatin are CYP3A4 substrates with significant grapefruit interaction raising the risk of myopathy. Statins should also be continued lifelong unless adverse effect or alternative therapy is indicated; self-discontinuation reverses CV benefit. Alcohol increases hepatotoxicity risk and is not therapeutic. Atorvastatin and rosuvastatin can be taken any time of day; short-acting simvastatin/lovastatin are taken in the evening.
In-depth explanation
Clinical reasoning summary Statin teaching priorities HMG-CoA reductase inhibitors (-statins) lower LDL by inhibiting hepatic cholesterol synthesis and have proven CV mortality reduction. Three patient-safety priorities: muscle symptom monitoring (myalgia is the most common adverse effect; new pain·weakness·tenderness·dark urine could indicate rhabdomyolysis — report immediately), hepatotoxicity monitoring (baseline LFT and as clinically indicated; report jaundice·RUQ pain·anorexia·dark urine), and drug/food interaction awareness — atorvastatin·simvastatin·lovastatin are CYP3A4 substrates with significant grapefruit interaction raising the risk of myopathy. Statins should also be continued lifelong unless adverse effect or alternative therapy is indicated; self-discontinuation reverses CV benefit. Alcohol increases hepatotoxicity risk and is not therapeutic. Atorvastatin and rosuvastatin can be taken any time of day; short-acting simvastatin/lovastatin are taken in the evening.